
Sotorasib provides durable clinical benefit for patients with non-small cell lung cancer and KRAS mutations
In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating ...
Jan 28, 2021
0
4